RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC
- Kazuhiko Nakagawa
- , Edward B. Garon
- , Takashi Seto
- , Makoto Nishio
- , Santiago Ponce Aix
- , Luis Paz-Ares
- , Chao Hua Chiu
- , Keunchil Park
- , Silvia Novello
- , Ernest Nadal
- , Kazumi Nishino
- , Kiyotaka Yoh
- , Jin Yuan Shih
- , Jeannie Y.K. Chik
- , Denis Moro-Sibilot
- , Tarun Puri
- , Sunoj Chacko Varughese
- , Bente Frimodt-Moller
- , Carla Visseren-Grul
- , Martin Reck
- Kindai University
- University of California at Los Angeles
- National Hospital Organization Kyushu Cancer Center
- Japanese Foundation for Cancer Research
- Hospital Universitario 12 de Octubre
- Taipei Medical University
- University of Turin
- Institute Catala Oncologia
- Osaka International Cancer Institute
- National Cancer Center Japan
- National Taiwan University
- Queen Elizabeth Hospital Hong Kong
- CHU de Grenoble
- Eli Lilly
- Eli Lilly Denmark A/S
- Eli Lilly Netherlands
- German Center of Lung Research
Research output: Contribution to journal › Article › peer-review
21
Link opens in a new tab
Scopus
citations